CRYSTAL CANTU: Open Payments
NPI 1477234250 · LUBBOCK, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,200 in 47 payments from 13 companies in 2025. Trend: 2023 $108 · 2024 $515 · 2025 $1,200
Food & beverage: $1,200
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 6 | $311 |
| GlaxoSmithKline, LLC. | 11 | $207 |
| Paratek Pharmaceuticals, Inc. | 14 | $168 |
| Abbott Laboratories | 6 | $140 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $114 |
| Kowa Pharmaceuticals America, Inc. | 1 | $102 |
| AstraZeneca Pharmaceuticals LP | 2 | $49 |
| Organon LLC | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| PFIZER INC. | 1 | $18 |
Products named: VRAYLAR, NUZYRA, AREXVY, QULIPTA, PERCLOSE PROGLIDE, CAPLYTA, ZORYVE, SHINGRIX.
Industry payments across TX — which companies pay providers there.
